BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33557878)

  • 21. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
    Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults With Prader-Willi Syndrome.
    Shukur HH; Hussain-Alkhateeb L; Farholt S; Nørregaard O; Jørgensen AP; Hoybye C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3634-e3643. PubMed ID: 33950234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.
    Angulo M; Castro-Magana M; Mazur B; Canas JA; Vitollo PM; Sarrantonio M
    J Pediatr Endocrinol Metab; 1996; 9(3):393-400. PubMed ID: 8887149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulated GH levels during the transition phase in Prader-Willi syndrome.
    Grugni G; Marzullo P; Delvecchio M; Iughetti L; Licenziati MR; Osimani S; Ragusa L; Salvatoni A; Sartorio A; Stagi S; Crinò A;
    J Endocrinol Invest; 2021 Jul; 44(7):1465-1474. PubMed ID: 33095904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
    Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
    Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial.
    Yang A; Choi JH; Sohn YB; Eom Y; Lee J; Yoo HW; Jin DK
    Orphanet J Rare Dis; 2019 Sep; 14(1):216. PubMed ID: 31511031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in carbohydrate metabolism and insulin resistance in patients with Prader-Willi Syndrome (PWS) under growth hormone therapy].
    Lämmer C; Weimann E
    Wien Med Wochenschr; 2007 Feb; 157(3-4):82-8. PubMed ID: 17340066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.
    Eiholzer U; l'Allemand D; van der Sluis I; Steinert H; Gasser T; Ellis K
    Horm Res; 2000; 53(4):200-6. PubMed ID: 11044804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome.
    Marzullo P; Marcassa C; Minocci A; Campini R; Eleuteri E; Gondoni LA; Aimaretti G; Sartorio A; Scacchi M; Grugni G
    J Clin Endocrinol Metab; 2015 May; 100(5):2106-14. PubMed ID: 25710568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of growth hormone treatment in adults with Prader-Willi syndrome.
    Butler MG; Smith BK; Lee J; Gibson C; Schmoll C; Moore WV; Donnelly JE
    Growth Horm IGF Res; 2013 Jun; 23(3):81-7. PubMed ID: 23433655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.
    Koizumi M; Ida S; Shoji Y; Nishimoto Y; Etani Y; Kawai M
    Endocr J; 2018 Nov; 65(11):1127-1137. PubMed ID: 30185718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.
    Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
    Acta Paediatr; 1998 Jan; 87(1):28-31. PubMed ID: 9510443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
    Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
    Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
    Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of growth hormone therapy in adults with Prader-Willi syndrome: A systematic review.
    Frixou M; Vlek D; Lucas-Herald AK; Keir L; Kyriakou A; Shaikh MG
    Clin Endocrinol (Oxf); 2021 Apr; 94(4):645-655. PubMed ID: 33296095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.